Roche subsidiary secures global rights to manufacture South Korean obesity treatment.
Roche acquires rights to an experimental obesity treatment
Keystone-SDA
Genentech, the Californian subsidiary of Swiss pharmaceutical giant Roche, has secured worldwide rights to develop, manufacture and market an experimental treatment for obesity from the South Korean company Hanmi Pharmaceuticals.
Generated with artificial intelligence.
This content was published on
Roche commits to lean-mass preservation with Hanmi obesity deal
Hanmi Pharm signs $2.3 bil. licensing deal with Roche's Genentech for obesity drug candidate - The Korea Times
Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
Hanmi signs record $2.3b obesity drug deal with Genentech
Hanmi dispara 30% após acordo de US$ 2,31 bi com subsidiária da Roche para tratamento de obesidade
Hanmi Pharm in spotlight as Korea's 1st obesity drug nears launch - The Korea Times
Fierce Pharma Asia—China's IIT scrutiny; Daiichi Sankyo, AZ ph. 3 win; Leo, Tanabe's dermatology deal
Correction to Roche Flash Headlines
